心脏抑制性反射失联:心脏神经衰竭作为治疗的替代方案
Amelie Beblo1, Robert Hättasch2, Nikolaos Dagres2
1Klinik für Kardiologie, Angiologie und Intensivmedizin, Campus Mitte, Deutsches Herzzentrum der Charité, Charitéplatz 1, 10117, Berlin, Germany. amelie.beblo@dhzc-charite.de.
Herzschrittmachertherapie & Elektrophysiologie
|August 28, 2025
概括
心脏神经衰竭 (CNA) 有效地治疗了一名患有复发性心脏抑制反射的年轻患者. 这种微创手术为特定患者提供了心脏起器的安全替代品.
科学领域:
- 心脏病学
- 电生理学
- 神经学
背景情况:
- 经常出现的反射失眠,特别是心脏抑制性失眠,会显著影响生活质量.
- 对于严重病例的传统治疗选择,如心脏起器植入,可能不适合所有患者,尤其是年轻人.
研究的目的:
- 在患有重度,复发性心脏抑制反射的年轻患者中报告成功的心脏神经衰竭 (CNA) 病例.
- 评估CNA作为安装心脏起器的安全有效替代方案.
主要方法:
- 一名36岁的女性患者经历了心动神经衰竭 (CNA).
- 使用可植入的循环记录器来确认诊断并监测患者的反应.
主要成果:
- 没有并发症进行心脏神经衰竭 (CNA).
- 患者的昏迷发作显著减少,证明了CNA的有效性.
结论:
- 心脏神经衰竭 (CNA) 是对年轻症状患者的复发性心脏抑制反射的可行且安全的治疗方法.
- 对于40岁以下的患者,当保守措施失败时,应考虑在专门中心进行CNA.
相关概念视频
Cardiopulmonary Resuscitation IV: Pharmacological Management
75
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
75
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
845
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
845
Dysrhythmias VI: Management of Dysrhythmias
106
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
106
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
985
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
985
Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717


